Composite For Liver-Specific Delivery and Release of Therapeutic Nucleic Acids or Drugs

a nucleic acid or drug technology, applied in the field of compound for liver-specific delivery of a therapeutic nucleic acid or a drug, can solve the problem of limited tissue-specific targeting and other problems, and achieve the effect of improving the efficiency of the liver

Inactive Publication Date: 2008-06-12
MOGAM BIOTECH RES INST
View PDF6 Cites 21 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, it has merely been demonstrated in vitro, but not in vivo, that the cellular uptake of the HDL carrier by a hepatoma cell line,

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composite For Liver-Specific Delivery and Release of Therapeutic Nucleic Acids or Drugs
  • Composite For Liver-Specific Delivery and Release of Therapeutic Nucleic Acids or Drugs
  • Composite For Liver-Specific Delivery and Release of Therapeutic Nucleic Acids or Drugs

Examples

Experimental program
Comparison scheme
Effect test

example 1

Preparation of the Inventive Composite

[0043]An equimolar mixture of 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP; Avanti Polar Lipids, USA) and cholesterol (Sigma, USA) was dispersed in chloroform and mixed to form a cationic liposome of DOTAP / cholesterol (DTC). After the liposome assembly was formed, the organic solvent was removed by evaporation under a stream of N2 gas and the residue was kept in a vacuum desiccator for 2 hours to ensure the removal of the residual organic solvent. The resulting dried film was hydrated in a 5% dextrose solution and the suspension thus obtained was sonicated using a bath sonicator. A solution containing 10% the Apo A-I purified in Test Example 1 was added thereto at a DTC: Apo A-I mix ratio of 10:1 (w / w), and the mixture was kept overnight at 4° C. to obtain the inventive composite (DTC-Apo).

example 2

Preparation of the Inventive Composite Containing Nucleic Acid

[0044]40 μg of HBV X gene-specific siRNA (SEQ ID NOs: 1 (sense) and 2 (antisense); Shin, D., Virus Res. (2006), 119: 146-153) was mixed with 400 μg of the inventive composite, DTC-Apo, in 200 μl of 5% dextrose solution and the mixture was incubated at room temperature for 30 min, to obtain the inventive composite containing HBV X gene-specific siRNA, named DTC-Apo / siHBV.

example 3

Preparation of the Inventive Composite Containing Nucleic Acid

[0045]The procedure of Example 2 was repeated except for using firefly luciferase-specific siRNA (SEQ ID NOs: 3 (sense) and 4 (antisense); Elbashir, S. M., Nature (2001), 411: 494-498) instead of HBV-specific siRNA, to obtain the inventive composite containing firefly luciferase-specific siRNA, named DTC-Apo / siLuc.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Weight ratioaaaaaaaaaa
Therapeuticaaaaaaaaaa
Pharmaceutically acceptableaaaaaaaaaa
Login to view more

Abstract

The inventive composite having a nanoscale particle size can specifically deliver therapeutic nucleic acids or drugs to the liver and selectively release them into hepatic cells to manifest potent therapeutic effects without inducing any enzymatic abnormalities or pathological damage to the normal liver function, when administered together with the therapeutic agents.

Description

FIELD OF THE INVENTION[0001]The present invention relates to a composite for liver-specific delivery of a therapeutic nucleic acid or a drug, a process for preparing the same and a composition comprising the same with a pharmaceutically acceptable carrier.BACKGROUND OF THE INVENTION[0002]A tissue-specific gene and drug delivery system has long been considered important for drug discovery and pharmaceutical advancement because most drugs are systemically delivered and circulated in the body when administered to a patient, which might adversely affect healthy organs or cells. The tissue-specific delivery system allows the accumulation of a high drug concentration at the target tissue which eliminating adverse side effects, leading to efficient treatment of tissue-specific diseases.[0003]Some liver diseases arise from infection by pathogenic viruses, e.g., HBV (hepatitis B virus) and HCV (hepatitis C virus), while non-infectious liver diseases result from exposure to liver-toxic materi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/127A61K31/7088
CPCA61K31/7088A61K9/1272A61P31/12A61P31/18A61P31/20A61P35/00A61K38/17
Inventor KIM, MEEHYEINKIM, SOO INSHIN, DUCKHYANGPARK, MAHNHOON
Owner MOGAM BIOTECH RES INST
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap